Literature DB >> 20021954

[Analysis of the therapeutic effect of esophagectomy with extended 2-field lymph node dissection for esophageal carcinoma].

Chang-rong Wu1, Heng-chuan Xue, Zong-hai Zhu, Zhen-bin Zhang, Chang-you Geng, Zhen-kai Ma, Yong Guo, Jie Gao.   

Abstract

OBJECTIVE: To summarize the surgical effect and clinical application value of esophagectomy with extended 2-field lymph node dissection for patients with esophageal carcinoma.
METHODS: From June 1987 to December 2008, 1690 patients with esophageal cancer underwent esophagectomy with extended 2-field (thoracic and abdominal) dissection of lymph nodes. Patients with the middle and lower thoracic esophageal cancer underwent Ivor-Lewis esophagectomy, and patients with upper thoracic esophageal cancer underwent Akiyama esophagectomy. 2-field (thoracic and abdominal) lymph node metastases information and the 1, 3, 5, 10-year survival rates were analyzed retrospectively.
RESULTS: Lymph node metastases were found in 713 patients. The lymph node metastases rate was 42.2% (713/1690).Thoracic lymph node metastasis rate was 39.3% (665/1690), among which in the right pleural apical para-tracheal triangle was 20.7% (349/1690), in the posterior upper mediastinum was 26.3% (444/1690), in the lower mediastinum was 18.2% (307/1690). Abdominal lymph node metastasis rate was 20.1% (339/1690). THE Postoperative complication rate was 16.4% (278/1690), among which the pulmonary complication rate ranking the first, was 43.6% (136/312). The operative mortality rate was 0.2%. The 1-year, 3-year, 5-year and 10-year survival rates were 88.2% (1388/1574), 63.5% (868/1367), 54.8% (705/1287) and 30.8% (232/754), respectively. The 5-year survival rate in patients without lymph node metastasis was 76.2% (448/588), but that in patients with lymph node metastases was 36.8% (257/669).
CONCLUSION: The results of this study demonstrated that Ivor-Lewis and Akiyama esophagectomy with two-field lymph node dissection exposes the operation fields clearly and make radical lymphadenectomy thoroughly, especially the lymph nodes in the posterior upper mediastinum around the recurrent laryngeal nerve and in the right pleural apical para-tracheal triangle. It is essential that patients with esophageal carcinoma with lymph node metastases should undergo esophagectomy with extended 2-field dissection of lymph nodes. This can elevate the postoperative 5-year survival rate remarkably.

Entities:  

Mesh:

Year:  2009        PMID: 20021954

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  3 in total

Review 1.  Society for Translational Medicine Expert consensus on the selection of surgical approaches in the management of thoracic esophageal carcinoma.

Authors:  Yousheng Mao; Zhentao Yu; Bin You; Wentao Fang; Brian Badgwell; Mark F Berry; DuyKhanh P Ceppa; Chun Chen; Haiquan Chen; Miguel A Cuesta; Xavier Benoit D'Journo; Guy D Eslick; Jianhua Fu; Xiangning Fu; Shugeng Gao; Jianxing He; Jie He; Yunchao Huang; Gening Jiang; Zhongmin Jiang; Jae Y Kim; Danqing Li; Hui Li; Shanqing Li; Deruo Liu; Lunxu Liu; Yongyu Liu; Xiaofei Li; Yin Li; Weimin Mao; Daniela Molena; Christopher R Morse; Nuria M Novoa; Lijie Tan; Qunyou Tan; Alper Toker; Ti Tong; Qun Wang; Benny Weksler; Lin Xu; Shidong Xu; Tiansheng Yan; Lanjun Zhang; Xingyi Zhang; Xun Zhang; Zhu Zhang; Xiuyi Zhi; Qinghua Zhou
Journal:  J Thorac Dis       Date:  2019-01       Impact factor: 2.895

2.  Effects of standard and total two-field lymph node dissection on prognosis of patients undergoing Esophagectomy.

Authors:  Qiang Guo; Hefei Li; Haibo Wang; Duo Zhang; Yonghui Li
Journal:  Pak J Med Sci       Date:  2022 Mar-Apr       Impact factor: 2.340

3.  Efficacy and safety of esophagectomy via left thoracic approach versus via right thoracic approach for middle and lower thoracic esophageal cancer: a multicenter randomized clinical trial (NST1501).

Authors:  You-Sheng Mao; Shu-Geng Gao; Yin Li; An-Lin Hao; Jun-Feng Liu; Xiao-Fei Li; Tie-Hua Rong; Jian-Hua Fu; Jian-Qun Ma; Mei-Qing Xu; Ren-Quan Zhang; Gao-Ming Xiao; Xiang-Ning Fu; Ke-Neng Chen; Wei-Min Mao; Yong-Yu Liu; Hong-Xu Liu; Zhi-Rong Zhang; Yan Fang; Dong-Hong Fu; Xu-Dong Wei; Li-Gong Yuan; Shan Muhammad; Wen-Qiang Wei; Philip Wai-Yan Chiu; Shane Lloyd; Francisco Schlottmann; Kenneth Meredith; Jose M Pimiento; Yi-Bo Gao; Jie He
Journal:  Ann Transl Med       Date:  2022-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.